Squarepoint Ops LLC Buys New Holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT)

Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics, Inc. (NASDAQ:BOLT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 48,971 shares of the company's stock, valued at approximately $26,000. Squarepoint Ops LLC owned 0.13% of Bolt Biotherapeutics at the end of the most recent quarter.

Separately, Citadel Advisors LLC bought a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at about $42,000. 86.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BOLT has been the subject of several recent research reports. Lake Street Capital initiated coverage on Bolt Biotherapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $80.00 price objective for the company. HC Wainwright restated a "neutral" rating on shares of Bolt Biotherapeutics in a report on Tuesday, March 25th. Finally, Stifel Nicolaus reduced their target price on shares of Bolt Biotherapeutics from $25.00 to $20.00 and set a "hold" rating for the company in a report on Tuesday, May 13th.

Bolt Biotherapeutics Stock Down 2.1%

Shares of BOLT traded down $0.13 during mid-day trading on Friday, hitting $6.10. 11,148 shares of the company traded hands, compared to its average volume of 10,664. Bolt Biotherapeutics, Inc. has a 1-year low of $5.20 and a 1-year high of $15.60. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The company has a market capitalization of $11.69 million, a PE ratio of -3.57 and a beta of 0.91. The business has a 50 day moving average of $6.73 and a 200 day moving average of $8.80.

Bolt Biotherapeutics (NASDAQ:BOLT - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($5.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.80) by $1.00. The firm had revenue of $1.22 million for the quarter, compared to the consensus estimate of $0.77 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Equities research analysts anticipate that Bolt Biotherapeutics, Inc. will post -1.61 EPS for the current year.

Bolt Biotherapeutics Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.